Racura cleared for next dose level in Phase I lung cancer trial
The Safety Review Committee (SRC) has approved Racura Oncology’s (ASX:RAC) progression to 100 mg/m2 of RC220 in the HARNESS-1 trial. Read more here.
The Safety Review Committee (SRC) has approved Racura Oncology’s (ASX:RAC) progression to 100 mg/m2 of RC220 in the HARNESS-1 trial. Read more here.
Share your feedback
Discover